After trial flop, Exelixis drops plan to pair Cabometyx with Roche’s Tecentriq in early-stage liver cancer

After trial flop, Exelixis drops plan to pair Cabometyx with Roche’s Tecentriq in early-stage liver cancer
fkansteiner
Tue, 03/15/2022 – 10:16